HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mitral Valve Insufficiency (Mitral Regurgitation)

Backflow of blood from the LEFT VENTRICLE into the LEFT ATRIUM due to imperfect closure of the MITRAL VALVE. This can lead to mitral valve regurgitation.
Also Known As:
Mitral Regurgitation; Mitral Insufficiency; Mitral Valve Regurgitation; Incompetence, Mitral; Incompetence, Mitral Valve; Insufficiency, Mitral; Insufficiency, Mitral Valve; Regurgitation, Mitral; Regurgitation, Mitral Valve; Valve Incompetence, Mitral; Valve Insufficiency, Mitral; Valve Regurgitation, Mitral; Mitral Incompetence; Mitral Valve Incompetence
Networked: 4087 relevant articles (243 outcomes, 402 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Heart Failure
2. Left Ventricular Dysfunction
3. Pulmonary Hypertension
4. Atrial Fibrillation
5. Cardiomyopathies (Cardiomyopathy)

Experts

1. Maisano, Francesco: 42 articles (09/2022 - 05/2003)
2. Mack, Michael J: 42 articles (01/2022 - 08/2006)
3. Alfieri, Ottavio: 34 articles (09/2022 - 05/2003)
4. Kar, Saibal: 32 articles (01/2022 - 01/2009)
5. Stone, Gregg W: 32 articles (01/2022 - 04/2004)
6. Bax, Jeroen J: 28 articles (01/2022 - 05/2005)
7. Abraham, William T: 27 articles (07/2022 - 04/2006)
8. Lindenfeld, JoAnn: 27 articles (07/2022 - 11/2018)
9. Taramasso, Maurizio: 27 articles (01/2022 - 03/2009)
10. Feldman, Ted: 27 articles (01/2021 - 12/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mitral Valve Insufficiency:
1. DobutamineFDA LinkGeneric
2. EnalaprilFDA LinkGeneric
3. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
4. pro-brain natriuretic peptide (1-76)IBA
5. Nitroprusside (Sodium Nitroprusside)FDA LinkGeneric
6. Brain Natriuretic Peptide (Natrecor)FDA Link
01/01/2020 - "Mitral regurgitation was significantly reduced after MitraClip implantation (3.7 ± 0.4 vs. 1.7 ± 0.8, P < 0.001), and the procedure was associated with improvement in brain natriuretic peptide levels (980 ± 1027 vs. 420 ± 338 pg/mL, P < 0.001), New York Heart Association class status (3.2 ± 0.55 vs. 2.0 ± 0.6, P < 0.001), 6-min walking test (233 ± 154 vs. 286 ± 114 m, P = 0.01) at follow-up and reduction of left ventricle end-systolic (LVESV) and left ventricle end-diastolic volumes (LVEDV) (152 ± 68 vs. 136 ± 43 mL, P = 0.004 & 219 ± 74 vs. 193 ± 66 mL, P = 0.001, respectively). "
01/15/2016 - "We sought to study the prognostic utility of serum brain natriuretic peptide (BNP) in patients with significant primary mitral regurgitation (MR) and preserved left ventricular (LV) ejection fraction (EF). "
01/01/2016 - "Studies suggesting that B-type natriuretic peptide (BNP) may predict outcomes of mitral regurgitation (MR) are plagued by small size, inconsistent etiologies, and lack of accounting for shifting normal BNP ranges with age and sex. "
09/15/2009 - "The purpose of the study was to determine the independent and additive prognostic value of brain natriuretic peptide (BNP) in patients with severe asymptomatic mitral regurgitation and normal left ventricular function. "
02/01/2008 - "The aim of this study was to define the correlation of the MPI with plasma B-type natriuretic peptide (BNP) levels and echocardiographic parameters in patients with chronic mitral regurgitation (MR). "
7. Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
8. Oxygen (Dioxygen)IBA
03/15/2003 - "Responders had significant improvement in 6-minute hall-walking distance (p = 0.006), metabolic equivalents (p = 0.02), peak oxygen uptake (p = 0.02), New York Heart Association functional class (p <0.001), and quality of life (p <0.001); an increase in the sphericity index (p = 0.007), ejection fraction (p <0.001), and diastolic filling time (p = 0.03); a decrease in myocardial performance index (p = 0.02), isovolumic relaxation time (p = 0.004), and mitral regurgitation (p = 0.007); and an improvement in systolic dyssynchrony (SD of the time to peak myocardial systolic contraction of the 12 LV segments as dyssynchrony index) (45.0 +/- 8.3 vs 32.5 +/- 14.5 ms, p = 0.003). "
07/01/2021 - "The aim of our study was to compare the levels of myocardial damage markers and the state of the oxygen budget in patients with mitral valve insufficiency during its surgical correction, depending on the method of cardioprotection. "
04/01/2006 - "The 67 patients completing the study presented with the following characteristics: age (70 +/- 10 years; 11 women); etiology (idiopathic in 44, ischemic in 23); NYHA class (40 in class III and 27 in class IV); LVEF 26% (+/-5%); QRS duration (190 +/- 28 ms); 6-minute walk test 330 m (+/-108); peak oxygen uptake 10.7 (+/-3.3 mL/kg/min); mitral insufficiency in 42 (> or =III grade); interventricular (IV) delay (62 +/- 21 ms); and intraventricular dyssynchrony in 30 patients. "
12/01/2021 - "Changes in peak exercise oxygen uptake (VO2 ) and cardiac output (CO) 6 months after successful percutaneous edge-to-edge mitral valve repair (pMVR) in severe primary (PMR) and functional mitral regurgitation (FMR) patients are unknown. "
07/01/2021 - "[COMPARISON OF LEVELS OF MYOCARDIAL INJURY MARKERS AND THE STATE OF THE OXYGEN BUDGET IN PATIENTS WITH MITRAL INSUFFICIENCY DURING SURGICAL CORRECTION, DEPENDING ON THE METHOD OF CARDIOPROTECTION]."
9. Vasodilator Agents (Vasodilators)IBA
10. Nifedipine (Adalat)FDA LinkGeneric

Therapies and Procedures

1. Therapeutics
2. Cardiac Resynchronization Therapy
3. Mitral Valve Annuloplasty
4. Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5. Transcatheter Aortic Valve Replacement